Quantitative assessment of the risk of lung cancer associated with occupational exposure to refractory ceramic fibers

Risk Analysis

Volumn 19, Issue 4, 1999, Pages 599-611

  Moolgavkar, Suresh H ^a,b   Luebeck, E Georg ^a   Turim, Jay ^b   Hanna, Linda ^b  

^a Fred Hutchinson Cancer Research Center   (United States)

^b Sciences International Inc   (United States)

Author keywords

Initiation; Monte Carlo methods; Promotion

Indexed keywords

CARCINOGENS; CERAMIC FIBERS; DISEASES; MATHEMATICAL MODELS; MONTE CARLO METHODS; OCCUPATIONAL RISKS;

INITIATION; LUNG CANCER; PROMOTION; REFRACTORY CERAMIC FIBERS;

RISK ASSESSMENT;

CANCER; HEALTH RISK; MEDICAL GEOGRAPHY; OCCUPATIONAL EXPOSURE; RISK ASSESSMENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER RISK; CARCINOGENESIS; CERAMICS; CONTROLLED STUDY; EXPERIMENTAL MODEL; LUNG CANCER; MALE; NONHUMAN; RAT; RISK ASSESSMENT;

ADMINISTRATION, INHALATION; ANIMALS; CARCINOGENS; CERAMICS; COCARCINOGENESIS; COHORT STUDIES; HUMANS; LIKELIHOOD FUNCTIONS; LUNG NEOPLASMS; MALE; MODELS, BIOLOGICAL; OCCUPATIONAL DISEASES; OCCUPATIONAL EXPOSURE; RATS; RATS, INBRED F344; RISK ASSESSMENT; SMOKING;

EID: 0033178102     PISSN: 02724332     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1007025417989     Document Type: Article

References (36)

1. Man-made Mineral Fibers and Radon, IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, Volume 1, (IARC, Lyon, France, 1988).
2. R. Saracci, L. Simonato, E. D. Acheson, A. Anderson, P. A. Bertazzi, et al., "Mortality and Incidence of Cancer of Workers in the Man Made Vitreous Fibres Producing Industry: An International Investigation at 13 European Plants," Br. J. Ind. Med. 41, 425-436 (1984).
3. M. J. Gardner, P. D. Winter, B. Pannett, M. J. C. Simpson, C. Hamilton, and E. D. Acheson, "Mortality Study of Workers in the Man-Made Mineral Fiber Production Industry in the United Kingdom," Scand. J. Work Environ. Health 12 (Suppl. 1), 85-93 (1986).
4. O. S. Miettinen and C. E. Rossiter, "Man-Made Mineral Fibers and Lung Cancer," Scand. J. Work Environ. Health 16, 221-231 (1990).
5. P. Gustavsson, N. Plato, O. Axelson, H. N. Brage, C. Hogsted, G. Ringback, G. Tornling, and G. Wingren, "Lung Cancer Risk Among Workers Exposed to Man-made Mineral Fibers (MMMF) in the Swedish Prefabricated House Industry," Am. J. Indust. Med. 21, 825-834 (1992).
6. J. E. Lockey, G. K. Lemasters, C. H. Rice, R. T. McKay, and P. S. Gartside, "A Retrospective Cohort Morbidity, Mortality and Nested Case-Control study of the Respiratory Health of Individuals Manufacturing Refractory Ceramic Fiber and RCF Products" (Department of Environmental Health, University of Cincinnati, Cincinnati, OH, 1993).
7. C. P. Yu, L. Zhang, G. Oberdoster, R. W. Mast, L. D. Maxim, and M. J. Utell, "Deposition of Refractory Ceramic Fibers (RCF) in the Human Respiratory Tract and Comparison with Rodent Studies," Aer. Sci. Tech. 23, 291 (1995).
8. S. H. Moolgavkar and A. G. Knudson, "Mutation and Cancer: A Model for Human Carcinogenesis," J. Natl. Cancer Inst. 66, 1037-1052.
9. S. H. Moolgavkar and G. Luebeck, "Two-Event Model for Carcinogenesis: Biological, Mathematical and Statistical Considerations," Risk Analysis 10, 323-341 (1990).
10. A. G. Knudson, "Mutation and Cancer: Statistical Study of Retinoblastoma," Proc. Natl Acad. Sci. USA 68, 820-823 (1971).
11. BEIR V, National Research Council, Committee on the Biological Effects of Ionizing Radiation, Health Effects of Exposure to Low Levels of Ionizing Radiation. (National Academy Press, Washington, DC, 1990).
12. R. Doll and R. Peto, "Cigarette Smoking and Bronchial Carcinoma: Dose and Time Relationships Among Regular Smokers and Lifelong Non-smokers," J. Epidemiol. Comm. Health 32, 303-313 (1978).
13. E. G. Luebeck, S. B. Curtis, F. T. Cross, and S. H. Moolgavkar, "Two-Stage Model of Radon-Induced Malignant Lung Tumors in Rats: Effects of Cell Killing," Radiat. Res 145, 163-173 (1996).
14. S. H. Moolgavkar, E. G. Luebeck, A. Buchmann, and K. W. Bock, "Quantitative Analysis of Enzyme-Altered Liver Foci in Rats Initiated with Diethylnitrosamine and Promoted with 2,3,7,8-Tetrachlorodibenzo-p-dioxin or 1,2,3,4,6,7,8-Heptachlorodibenzo-p-dioxin," Toxicol. Appl. Pharmacol. 138, 31-42 (1996).
15. S. H. Moolgavkar, E. G. Luebeck, D. Krewski, and J. M. Zielinski, "Radon, Cigarette Smoke and Lung Cancer: A Re-analysis of the Colorado Plateau Uranium Miners' Data," Epidemiology 4, 204-217 (1993).
16. M. Kai, E. G. Luebeck, and S. H. Moolgavkar, "Analysis of Solid Cancer Incidence Among Atomic Bomb Survivors Using a Two-Stage Model of Carcinogenesis," Radiat. Res. 148, 348-358 (1997).
17. M. P. Little, "Generalisation of the Two-Mutation and Classical Multi-Stage Models of Carcinogenesis Fitted to the Japanese Atomic Bomb Survivor Data," J. Radiol. Protect. 16, 7-24 (1996).
18. M. P. Little, C. R. Muirhead, and C. A. Stiller, "Modelling Lymphocytic Leukemia Incidence in England and Wales Using Generalizations of the Two-Mutation Model of Carcinogenesis of Moolgavkar, Venzon and Knudson," Stat. Med. 15, 1003-1022, (1996).
19. C. E. Rossiter and J. R. Chase, "Statistical Analysis of Results of Carcinogenicity Studies of Synthetic Vitreous Fibres at Research and Consulting Company, Geneva," Ann. Occup. Hyg. 39, 759-769 (1995).
20. S. M. Cohen and L. B. Ellwein, "Cell Proliferation in Carcinogenesis," Science 249, 1007-1011 (1990).
21. P. Armitage and R. Doll, "The Age Distribution of Cancer and a Multi-stage Theory of Carcinogenesis," Br. J. Cancer 8, 1-12 (1954).
22. S. H. Moolgavkar and D. J. Venzon, "Two-Event Models for Carcinogenesis: Incidence Curves for Childhood and Adult Tumors," Math. Biosci. 47, 55-77 (1979).
23. S. H. Moolgavkar and E. G. Luebeck, "Multistage Carcinogenesis: A Population-Based Model for Colon Cancer," J. Natl. Cancer Inst. 84, 610-618 (1992).
24. W. F. Heidenreich, "On the parameters of the clonal expansion model," Radiat. Environ. Biophys. 35, 127-129 (1996).
25. W. F. Heidenreich, E. G. Luebeck, and S. H. Moolgavkar, "Some Properties of the Hazard Function of the Two-Mutation Clonal Expansion Model," Risk Analysis 17, 391-399 (1997).
26. W. R. Gilks, S. Richardson, and D. J. Spiegelhalter (eds.), Markov Chain Monte Carlo in Practice (Chapman and Hall, New York, 1996).
27. A. F. Raftery and S. M. Lewis, "Implementing MCMC," in W. R. Wilks, S. Richardson, and D. J. Spiegelhalter (eds.), Markov Chain Monte Carlo in Practice (Chapman and Hall, New York, 1996), pp. 115-130.
28. S. H. Moolgavkar and E. G. Luebeck, "A Two-Mutation Model for Radiation Carcinogenesis in Humans and Rodents," in O. H. Iversen (ed.), New Frontiers in Cancer Causation (Taylor and Francis, Washington, DC, 1993), pp. 199-210.
29. R. Peto, A. D. Lopez, J. Boreham, M. Thun, and C. Heath, Jr., "Mortality from Tobacco in Developed Countries: Indirect Estimation from National Vital Statistics," Lancet 339, 1268-1278 (1992).
30. J. C. Barrett, P. W. Lamb, and R. W. Wiseman, "Multiple Mechanisms for the Carcinogenic Effects of Asbestos and Other Mineral Fibers," Environ. Health Perspect. 81, 81-92 (1989).
31. P. Voytek, M. Anver, T. Thorslund, J. Conley, and E. Anderson, "Mechanisms of Asbestos Carcinogenicity," J. Am. College Toxicol. 9, 541-550 (1990).
32. J. I. Everitt, "Mechanisms of Fiber-Induced Diseases: Implications for the Safety Evaluation of Synthetic Vitreous Fibers." Regul. Toxicol. Pharmacol. 20, S68-S75 (1994).
33. D. W. Berman, K. S. Crump, E. J. Chatfield, J. M. G. Davis, and A. D. Jones, "The Sizes, Shapes, and Mineralogy of Asbestos Structures That Induce Lung Tumors or Mesothelioma in AF/HAN Rats Following Inhalation," Risk Analysis 15, 181-195 (1995).
34. U. S. Environmental Protection Agency, Methods for Derivation of Inhalation Reference Concentrations and Application in Inhalation Dosimetry, EPA/600/8-90-066F (U.S. Environmental Protection Agency, Research Triangle Park, NC, 1994).
35. U.S. Environmental Protection Agency, Exposure Factors Handbook (Office of Health and Environmental Assessment, 1989).
36. C. P. Yu, Y. J. Ding, L. Zhang, G. Oberdoster, R. W. Mast, L. D. Maxim, and M. J. Utell, "Retention Modeling of Refractory Ceramic Fibers (RCF) in Humans," Regul. Toxicol. Pharmac. 25, 18-25 (1997).